Multiple studies have been completed or are currently underway.
The FML-204 study was a prospective study of 41 patients to evaluate the safety and efficacy of non-invasive, non-radiating bioconductance measurements in distinguishing between malignant and benign lung lesions. No adverse events reported.
What is Sensitivity and Specificity?
Specificity (also called the true negative rate) measures the proportion of negatives that are correctly identified as such (i.e., the percentage of healthy people who are correctly identified as not having the condition).
Sensitivity (also called the true positive rate) measures the proportion of positives that are correctly identified as such (i.e. the percentage of affected people who are correctly identified as having the condition).
The primary study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. A statistically significant result will indicate that patients with a high ProLung Test result have a greater risk of developing lung cancer than patients with a low test result.
If you have been diagnosed with an indeterminate pulmonary nodule, you may eligible to participate in the ProLung clinical trial. Fill out the form below and we will connect you to the nearest testing location.